

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIAALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 6

Dkt: 875.039US1

CLEAN VERSION OF PENDING CLAIMS

1. [Once Amended] A method to normalize the contractile response of an endothelially-compromised vascular smooth muscle cell to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.
6. A method of claim 23, wherein the wherein the compound administered is 1-p- β -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
7. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result of diabetes.
8. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result of a surgical procedure.
9. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result or cause of hypertension.
10. [Previously Once Amended] A method of claim 23, wherein said endothelium damage is the result or cause of coronary artery disease.
11. [Previously Once Amended] A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.111

Serial Number: 09/512,926


Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELLALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 7

Dkt: 875.039US1

23. [Once Amended] A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R^4 is H or a lower alkyl radical and R^5 is a lower alkyl radical, or R^4 and R^5 are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R^6 is H or a lower alkyl radical;

R^7 is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R^8 is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.